Company Overview - Pfizer (PFE -0 07%) stock investors are curious about the valuation and prospects for the healthcare company [1] Stock Performance - Stock prices used were the afternoon prices of Jan 1 2025 [1] - The video discussing the stock was published on Jan 3 2025 [1]

分组1 - The Motley Fool holds positions in and recommends Pfizer [1] - Parkev Tatevosian is affiliated with The Motley Fool and may receive compensation for promoting its services [1] - Parkev Tatevosian's opinions are independent and not influenced by The Motley Fool [1]

Stock Performance & Valuation - Pfizer's stock has risen 5.6% in the past month due to encouraging 2025 guidance [1] - The stock has declined 8.4% in the past year compared to a 1.9% decrease for the industry [11] - Pfizer's forward P/E ratio of 9.05 is lower than the industry's 15.73 and its 5-year mean of 11.26 [12] - The Zacks Consensus Estimate for 2025 EPS has risen from $2.91 to $2.92 over the past 30 days [15] Financial Guidance & Projections - Pfizer projects 2025 revenues between $61.0 billion and $64.0 billion, representing flat to 5% operational growth from 2024 [1] - Adjusted EPS is expected to be $2.80 to $3.00 in 2025, representing 10% to 18% operational growth year-over-year [1] - The company expects 2025-2030 revenue CAGR of approximately 6% [7] COVID-19 Products - Sales of COVID products Comirnaty and Paxlovid are declining due to lower post-pandemic demand [4] - Pfizer expects these products to maintain market share in 2025 with stable pricing [4] - There is uncertainty around COVID product sales as they depend on infection rates [5] Growth Drivers - Non-COVID operational revenues improved in 2024, driven by key products like Vyndaqel and Eliquis [6] - The Seagen acquisition contributed $2.3 billion in sales in the first nine months of 2024, up 38% proforma [8] - Pfizer expects Seagen to contribute over $10 billion in risk-adjusted revenues by 2030 [8] - Oncology sales grew 26% operationally in the first nine months of 2024 and comprise over 26% of total revenues [9] Challenges - Declining sales of COVID-19 products pose a challenge [18] - Loss of patent exclusivity for key products in 2026-2030 will have a significant impact [18] - The Medicare Part D redesign under the Inflation Reduction Act may hurt sales of higher-priced drugs [18] Financial Position & Strategy - Pfizer has a strong cash position from COVID product profits, used for acquisitions, dividends, share buybacks, and debt reduction [19] - The company expects cost cuts and restructuring to deliver at least $5.5 billion in savings [19] - Pfizer offers an attractive dividend yield of around 6.3% [19] Pipeline & Future Outlook - Pfizer has a strong late-stage pipeline and expects to have eight or more blockbuster oncology medicines by 2030 [9] - The company markets six oncology biosimilars and advanced its oncology clinical pipeline in 2024 [9] - Non-COVID drugs and newly acquired products are expected to continue driving growth [19]

For Immediate ReleasesChicago, IL – January 3, 2024 – Zacks.com announces the list of stocks and featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Berkshire Hathaway Inc. (BRK.B) , The Home Depot, Inc. (HD) , Pfizer Inc. (PFE) and AMREP Corp. (AXR) .Here are highlights from Friday’s Analyst Blog:Top Research Reports for Berkshire Hathaway, Home Depot and Pfizer ...

Policy Impact on Vaccine Stocks - The selection of Robert F Kennedy Jr to lead the Department of Health and Human Services is putting pressure on vaccine stocks, potentially signaling cautious investors to avoid Pfizer Inc (PFE) [1] - Pfizer stock has historically underperformed in January, with an average loss of 4 6% over the past 10 years and finishing the month in the red eight times [2] Pfizer Stock Performance - Pfizer stock is currently at $26 39, with a potential drop to $25 if historical trends continue [2] - The stock is down 8 2% in 2024 but is on track for a small December gain, breaking a four-month losing streak [3] - The stock recently dipped to $24 48 on Nov 15, its lowest level since January 2013 [3] Options and Volatility - Pfizer's Schaeffer's Volatility Index (SVI) is at 20%, ranking in the 11th percentile over the last 12 months, making options an attractive route [4] - The Schaeffer's Volatility Scorecard (SVS) for Pfizer is relatively low at 30 out of 100, indicating it is a prime candidate for short-term selling [4] - The Schaeffer's put/call open interest ratio (SOIR) of 0 55 is in the 1st percentile, showing a preference for calls among short-term traders [7] Historical January Performance - Pfizer is among the worst-performing S&P 500 stocks in January, with a median return of -2 75% and only 20% positive returns historically [5] - Other stocks with poor January performance include UPS (-4 81%), ABBV (-4 36%), and HUM (-2 71%) [5] Recent Trading Data - Pfizer's daily chart since January 2024 shows a trading range of $26 24 to $26 57, with a closing price of $26 34, down 1 05% [6]

JHVEPhoto Listen here or on the go via Apple Podcasts and Spotify Why Kirk Spano sees Pfizer as one of the next big winners from AI and why he thinks investors should be selling cash secured puts. This is an excerpt from a recent episode. Subscribe to Kirk's Margin of Safety Investing Group Transcript Kirk Spano: I think Pfizer (NYSE:PFE) is one of the next big winners from AI. Will it take two or three years? Probably. But I think that Pfizer is in that group of pharmaceutical companies with a ton o ...

Pfizer's Strategic Moves - Pfizer launched a record 19 new products or indications in 18 months to compensate for declining coronavirus product sales [2] - The company made a $43 billion acquisition of Seagen, an oncology specialist focused on antibody-drug conjugates (ADCs) [2] - Pfizer aims to have eight or more oncology blockbusters on the market by 2030, leveraging Seagen's strong ADC pipeline [11] Financial Performance and Market Position - Pfizer's oncology portfolio, including Seagen products, delivered over 30% revenue growth in the recent quarter [3] - The company became the third-largest U.S. oncology company by sales in the first half of the year [3] - Pfizer generated over $100 billion in total revenue in 2022, largely due to its coronavirus vaccine and treatment [8] Challenges and Future Outlook - Pfizer's earnings and share price have declined by over 50% in the past three years due to waning demand for coronavirus products [4] - The company expects to lose $17 billion in revenue from 2025 through 2030 due to the expiration of key patents for drugs like Eliquis and Ibrance [10] - The Seagen acquisition is predicted to help Pfizer stock take off by 2025, making it an opportune time to invest in the company [7][9] Seagen's Contribution to Growth - Seagen's drugs, including Adcetris, Padcev, Tukysa, and Tivdak, have seen significant revenue growth, with Padcev's revenue doubling to over $400 million [11] - The acquisition has strengthened Pfizer's expertise in oncology and is expected to drive future growth [9][11] Historical Context - Pfizer has been in operation for 175 years, historically selling a broad range of drugs for various indications [5] - The company gained significant attention during the pandemic with the development of its coronavirus products, which initially drove substantial growth [5]

Zacks Rank and Stock Performance - The Zacks Rank system has a strong track record, with 1 stocks generating an average annual return of +25% since 1988 [1] - Pfizer currently holds a Zacks Rank of 2 (Buy) [1] - Pfizer's stock closed at $26 56, marking a -0 67% move from the previous day, underperforming the S&P 500's daily loss of 0 04% [2] - Over the past month, Pfizer's shares appreciated by 3 52%, outperforming the Medical sector's loss of 4 31% and the S&P 500's gain of 1 05% [2] Earnings and Revenue Projections - Pfizer's upcoming earnings per share (EPS) are projected to be $0 48, reflecting a 380% increase from the same quarter last year [3] - Revenue for the upcoming quarter is anticipated to be $17 48 billion, indicating a 22 67% upward movement from the same quarter last year [3] - For the full year, earnings are projected at $2 91 per share, representing a +58 15% change from the prior year [4] - Full-year revenue is estimated at $63 34 billion, reflecting an +8 28% change from the prior year [4] Valuation Metrics - Pfizer is currently traded at a Forward P/E ratio of 9 18, marking a discount compared to its industry's average Forward P/E of 13 9 [9] - Pfizer has a PEG ratio of 0 65, significantly lower than the Large Cap Pharmaceuticals industry average PEG ratio of 1 46 [11] Industry and Analyst Insights - The Large Cap Pharmaceuticals industry has a Zacks Industry Rank of 136, placing it in the bottom 46% of all 250+ industries [10] - Analyst estimate revisions for Pfizer reflect the latest short-term business trends and can indicate confidence in the company's performance [5] - Research shows that estimate alterations are directly linked with near-future stock price performance [6]

High-yield dividend stocks often catch investors' attention -- and for good reason. When established companies maintain larger-than-average dividend payments, they can provide both substantial current income and the potential for long-term appreciation.However, unusually high yields can be a double-edged sword. Sometimes, they reflect temporary market pessimism, creating genuine value opportunities. Other times, they signal legitimate concerns about a company's ability to maintain its dividend payments in t ...

Pfizer hosted a discussion with sell-side analysts to provide an update on one of the vaccine pipeline items – a second-generation Clostridioides difficile (C. diff) vaccine effort in Phase 2.Goldman Sachs analyst Chris Shibutani maintained a Buy rating on Pfizer, Inc PFE with a price target of $33.Shibutani recalled that Pfizer had reported negative results from a Phase 3 study for a first-generation asset in March 2022, where the primary endpoint was unmet.Also Read: Elon Musk’s xAI To Expand With New Cha ...